Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma
- Yumiko Yamamoto
- Yoshihiro Hayashi
- Hideyuki Sakaki
- Ichiro Murakami
Affiliations: Department of Diagnostic Pathology, Kochi University Hospital, Kochi University, Nankoku, Kochi 783‑8505, Japan, Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783‑8505, Japan, Department of Nutritional Sciences for Well‑being Health, Kansai University of Welfare Sciences, Kashiwa, Osaka 582‑0026, Japan
- Published online on: August 8, 2021 https://doi.org/10.3892/mco.2021.2361
Copyright: © Yamamoto
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Fascin‑1, an actin‑bundling protein, is associated with poor prognosis in patients with various types of human carcinoma. However, research is limited on the role of fascin‑1 in sarcoma. Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) are rare sarcomas derived from the mesenchyme. Although the prognosis of SFT/HPC is generally favorable, fatalities are possible with repeated recurrence and distant metastasis. The current study included a total of 20 Japanese patients, who were diagnosed with SFT/HPC and underwent surgery at Kochi University Hospital from January 2000 to December 2019. The statistical relationship between recurrence and the following variables were examined: Sex, age of onset, tumor origin, tumor size, necrosis, mitosis ≥1/10 high power field (HPF; magnification, x400), Ki‑67 >5% and Fascin‑1. A significant association was determined between recurrence and necrosis, mitosis ≥1/10 HPF (magnification, x400), Ki‑67 >5%, and Fascin‑1 ≥‘strongly positive’ (P<0.05). The results demonstrated that Fascin‑1 immunostaining may be a highly effective and useful evaluation factor for predicting poor prognosis in patients with SFT/HPC, a fatal sarcoma of humans.